Clinical trials: Chronic Obstruct Airways Disease
COPD Exacerbation Acute
A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease, that causes obstructed airflow from the lungs that causes persistent obstructive airflow limitation.
- Trial name
- NCT05400369
- Testing
- Sitafloxacin, Moxifloxacin Hydrochloride
- Where
- 18 sites in China
- Volunteers
- 140 people
- Sponsor
- Daiichi Sankyo
Pulmonary Disease, Chronic Obstructive, Lung Diseases
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Lung Diseases, Obstructive
- Trial name
- A7881013 (NCT00808288)
- Testing
- PF-00610355, PF - 00610355, PF- 00610355
- Where
- 75 sites in United States, Argentina and 10 more
- Volunteers
- 405 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444.
- Trial name
- COPD (NCT01323660)
- Testing
- GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719 125
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 307 people
- Sponsor
- GlaxoSmithKline
Chronic Bronchitis, Chronic Obstructive Pulmonary Disease
A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)
The purpose of this study was to evaluate the effect of ION-827359 on forced expiratory volume in 1 second (FEV1) in participants with mild to moderate COPD with CB.
- Trial name
- NCT04441788
- Testing
- ION-827359
- Where
- 15 sites in Czechia, Germany and 2 more
- Volunteers
- 60 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Asthma
Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple Indications
Glucocorticoids are important in the treatment of many inflammatory, allergic, immunologic, and malignant disorders. However, the adverse effects of systemic corticosteroids are one of the most common causes of iatrogenic…
- Trial name
- NCT06488703
- Where
- Germany
- Volunteers
- 107,032 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the efficacy and safety of GSK233705B compared with placebo in subjects with COPD.
- Trial name
- NCT00676052
- Testing
- GSK233705 12.5mcg, GSK233705 25mcg, GSK233705 50mcg
- Where
- 88 sites in United States, Argentina and 12 more
- Volunteers
- 576 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
An investigational inhalation product (QVA149) for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) is being developed.
- Trial name
- NCT00558285
- Testing
- indacaterol/glycopyrrolate, indacaterol, glycopyrrolate
- Where
- 40 sites in Australia, Belgium and 6 more
- Volunteers
- 257 people
- Sponsor
- Novartis
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week…
- Trial name
- NCT05612035
- Testing
- Frespaciguat
- Where
- 85 sites in United States, Argentina and 17 more
- Volunteers
- 129 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Disease, Chronic Obstructive
Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation caused by inflammation-mediated damage to lung tissue.
- Trial name
- NCT01387178
- Testing
- fluticasone propionate/salmeterol 250µg/50µg (FSC), tiotropium bromide (TIO)
- Volunteers
- 22,223 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
Study is to show that QVA149 is superior to the standard of care, fluticasone/salmeterol, in patients with moderate to severe airflow limitation
- Trial name
- NCT01834885
- Testing
- QVA149, fluticasone/salmeterol
- Where
- 29 sites in Austria, Germany
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Correlation Between Patient Perception and Findings on Clinical Examination in Chronic Obstructive Pulmonary Disease (COPD) Patients
This is a multi-center, prospective, non-interventional study that aims to evaluate in daily clinical practice the possible correlation between patient perception of the ability to perform morning activities and the physician's…
- Trial name
- RELIEF (NCT01703416)
- Where
- 2 sites in Bulgaria
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
HandiHaler® vs. Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Trial to compare the administration technique for HandiHaler® vs. MDI, to compare the learning retention of the administration technique for the HandiHaler® vs. MDI and to compare the ease of use for HandiHaler® vs. MDI
- Trial name
- NCT02172404
- Testing
- Ipratropium metered dose inhaler (MDI)
- Volunteers
- 160 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this trial is to determine whether treatment with tiotropium (18 mcg) capsule once daily via the HandiHaler reduces the proportion of patients with COPD experiencing an exacerbation and the proportion of…
- Trial name
- NCT00274547
- Testing
- Tiotropium
- Where
- 26 sites in United States
- Volunteers
- 1,829 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Lung Disease (COLD)
Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD
This clinical trial evaluates the long-term safety and efficacy of 0.75 mg HSK39004 Dry Powder Inhaler administered twice daily for 52 weeks in subjects aged 40 to 80 years with moderate-to-severe stable chronic obstructive…
- Trial name
- NCT07425210
- Testing
- HSK39004 Dry Powder Inhaler -0.75mg BID
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease
Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study was to determine whether potentiating the cystic fibrosis transmembrane conductance regulator (CFTR) with QBW251 in subjects with COPD would be efficacious with regards to reducing lung and systemic…
- Trial name
- NCT04268823
- Testing
- QBW251
- Where
- 12 sites in Austria, Germany and 2 more
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the safety and efficacy of inhaled PT005 compared to placebo and Formoterol Fumarate (Foradil Aerolizer) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00880490
- Testing
- Inhaled PT005, Formoterol Fumarate 12 mcg (Foradil Aerolizer)
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 34 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Validation of Structured Light Plethysmography - Health and Disease
Validation of Structured Light Plethysmography (SLP) in patients with conditions such as Chronic Obstructive Pulmonary Disease (COPD) that effect breathing and in healthy participants.
- Trial name
- SLP-RespDis (NCT02626468)
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Pneumacare Ltd
Chronic Obstructive Pulmonary Disease
Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The primary objective of this study is to assess the efficacy of Glycopyrrolate/Formoterol Fumarate MDI relative to individual components (GP MDI and FF MDI) in subjects with moderate to severe COPD
- Trial name
- NCT01587079
- Testing
- PT003, PT001, PT005
- Where
- 19 sites in United States
- Volunteers
- 159 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
A Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is characterized by a progressive decline in lung function and increased symptoms such as breathlessness/dyspnoea, cough and expectoration.
- Trial name
- COPD Language (NCT01219946)
- Where
- 32 sites in Greece
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to demonstrate the efficacy of inhaled treprostinil compared to placebo in improving exercise ability as measured by change from baseline in 6-Minute Walk Distance (6MWD) following 12 weeks…
- Trial name
- PERFECT (NCT03496623)
- Testing
- Inhaled treprostinil solution
- Where
- 76 sites in United States, Argentina and 2 more
- Volunteers
- 188 people
- Sponsor
- United Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.